These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 6227373

  • 1. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
    Gundlach AL, Krstich M, Beart PM.
    Brain Res; 1983 Nov 14; 278(1-2):155-63. PubMed ID: 6227373
    [Abstract] [Full Text] [Related]

  • 2. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states.
    George SR, Watanabe M, Seeman P.
    J Neurochem; 1985 Apr 14; 44(4):1168-77. PubMed ID: 2579204
    [Abstract] [Full Text] [Related]

  • 3. Competitive inhibition of [3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations.
    De Vries DJ, Beart PM.
    Eur J Pharmacol; 1984 Oct 30; 106(1):133-9. PubMed ID: 6241565
    [Abstract] [Full Text] [Related]

  • 4. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes.
    Hamblin MW, Leff SE, Creese I.
    Biochem Pharmacol; 1984 Mar 15; 33(6):877-87. PubMed ID: 6712712
    [Abstract] [Full Text] [Related]

  • 5. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P, Olianas MC, Gessa GL.
    Mol Pharmacol; 1985 Aug 15; 28(2):138-45. PubMed ID: 2410769
    [Abstract] [Full Text] [Related]

  • 6. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone.
    Lazareno S, Nahorski SR.
    Eur J Pharmacol; 1982 Jul 09; 81(2):273-85. PubMed ID: 7117377
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Complete conversion of brain D2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide.
    Grigoriadis D, Seeman P.
    J Neurochem; 1985 Jun 09; 44(6):1925-35. PubMed ID: 3157782
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
    Fuxe K, Agnati LF, Köhler C, Kuonen D, Ogren SO, Andersson K, Hökfelt T.
    J Neural Transm; 1981 Jun 09; 51(1-2):3-37. PubMed ID: 7264628
    [Abstract] [Full Text] [Related]

  • 18. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.
    Neve KA, Altar CA, Wong CA, Marshall JF.
    Brain Res; 1984 Jun 04; 302(1):9-18. PubMed ID: 6428705
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.
    Leff SE, Hamblin MW, Creese I.
    Mol Pharmacol; 1985 Feb 04; 27(2):171-83. PubMed ID: 3969066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.